# Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

> **NCT00083694** · PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 25 (—)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00083694
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 25 (—)
- **Last updated:** 2010-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083694, "Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00083694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*